+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Inflammatory Bowel Disease (Crohn's) & Ulcerative Colitis: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797455
  • Drug Pipelines
  • 518 pages
  • Datamonitor Healthcare
1 of 2
Strong growth in the IBD market during 2014-23 is forecast, driven by the lucrative US market, with the impact of new product launches expected to outweigh downward pressure from biosimilar competition.

This report addresses the following questions:

- What impact will biosimilars have on market-leading drugs for IBD and when will key biosimilar launches occur in each market?
- What do surveyed gastroenterologists consider to be the biggest prescribing influences for Crohn’s disease and ulcerative colitis?
- How does biologic prescribing differ for Crohn’s disease and ulcerative colitis and where is the greatest commercial potential?
- What are the remaining unmet needs for Crohn’s disease and ulcerative colitis, and how are their pipelines addressing these needs?
Note: Product cover images may vary from those shown
2 of 2
FORECAST: INFLAMMATORY BOWEL DISEASE & Ulcerative Colitis

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Cimzia (certolizumab)
- CX6
- Entyvio (vedolizumab),
- Etrolizumab,
- Humira (adalimumab),
- LT-02,
- Remicade (infliximab),
- Simponi (golimumab),
- Stelara (ustekinumab),
- Tysabri (natalizumab),
- Xeljanz (tofacitinib),
- Primary Research Methodology

TREATMENT: INFLAMMATORY BOWEL DISEASE

- Executive Summary
- Primary Research Methodology
- Patient Segmentation
- Country Treatment Trees: Crohn’s Disease
- Country Treatment Trees: Ulcerative Colitis
- Current Treatment Options
- Prescribing Trends: Crohn’s Disease
- Prescribing Trends: Ulcerative Colitis
- Prescribing Influences
- Unmet Needs in Inflammatory Bowel Disease

EPIDEMIOLOGY: ULCERATIVE COLITIS

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Appendix

EPIDEMIOLOGY: CROHN’S DISEASE

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Appendix

MARKETED DRUGS: INFLAMMATORY BOWEL DISEASE

- Executive Summary
- Product Overview
- Product profile: Apriso
- Product profile: Cimzia
- Product profile: Delzicol/Asacol HD
- Product profile: Entyvio
- Product profile: Humira
- Product profile: Lialda
- Product profile: Pentasa
- Product profile: Remicade
- Product profile: Simponi
- Product profile: Tysabri
- Product profile: Uceris

PIPELINE: INFLAMMATORY BOWEL DISEASE

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Recently Discontinued Drugs
- Product profile (late stage): Cx6
- Product profile (late stage): LT-
- Product profile (late stage): Stelara
- Product profile (late stage): Xeljanz
- Product profile (late stage): etrolizumab

APPENDIX

- Appendix: Marketed Drugs: Inflammatory Bowel Disease
- Appendix: Pipeline: Inflammatory Bowel Disease
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll